BriaCell Therapeutics Corp. (OTCMKTS:BCTXF – Get Free Report)’s share price dropped 39.9% on Thursday . The company traded as low as $0.60 and last traded at $0.66. Approximately 7,893,152 shares were traded during mid-day trading, an increase of 424,491% from the average daily volume of 1,859 shares. The stock had previously closed at $1.10.
BriaCell Therapeutics Stock Performance
The firm’s 50-day moving average price is $0.85 and its 200-day moving average price is $0.89. The stock has a market capitalization of $509,520.00, a PE ratio of -0.17 and a beta of 1.09.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT.
Featured Articles
- Five stocks we like better than BriaCell Therapeutics
- Bank Stocks – Best Bank Stocks to Invest In
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Using the MarketBeat Dividend Yield Calculator
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
